Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma
- PDF / 429,496 Bytes
- 7 Pages / 595.276 x 793.701 pts Page_size
- 26 Downloads / 187 Views
RESEARCH
Open Access
Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma Bin-Kui Li1,2, Pin-Zhu Huang1,2, Ji-Liang Qiu1,2, Ya-Di Liao1,2, Jian Hong1,2 and Yun-Fei Yuan1,2*
Abstract Background: MicroRNA-106b (miR-106b) is a member of the miR-106b ~ 25 cluster. It has been reported that miR-106b acts as an oncogene and is upregulated in many human cancers. However, the prognostic value of miR-106b in hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to investigate the clinical significance of miR-106b expression in HCC. Methods: We determined the expression level of miR-106b in 104 cases of paired HCC and adjacent non-tumor tissues by quantitative real-time PCR (qRT-PCR). The correlation between miR-106b expression and prognosis of HCC was studied by univariate and multivariate analysis. Multivariate analysis of the prognostic factors was performed with Cox proportional hazards model. Results: MiR-106b expression was significantly upregulated in as high as 76.0% of HCC tissues, compared with their non-tumor counterparts (P < 0.001). High miR-106b expression was significantly associated with large tumor size (P = 0.019) and vascular invasion (P = 0.016). Kaplan-Meier analysis showed that patients with high miR-106b expression had a worse overall survival than patients with low miR-106b expression (log-rank P = 0.004). The multivariate Cox regression analysis indicated that miR-106b expression was an independent prognostic factor for overall survival (HR, 2.002; 95% CI, 1.130-6.977; P = 0.027). Conclusion: Our data indicated that miR-106b expression was significantly upregulated in HCC and could serve as a potential unfavorable prognostic biomarker. Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/ vs/13000_2014_226 Keywords: Hepatocellular carcinoma, miR-106b, Prognosis
Background Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with poor prognosis [1]. Accurate prediction of prognosis and patient stratification are crucial for guiding patients’ personalized clinical treatment. These are currently performed by clinical and/or pathological staging systems [2-4]. Recently important progress has been made with using comprehensive approaches to identify the molecular diversity in HCC. A large number of genetic and epigenetic abnormalities were found during the process of HCC development [5-8]. Consequently, many new prognostic * Correspondence: [email protected] 1 State Key Laboratory of Oncology in South China, Guangzhou, China 2 Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China
biomarkers of HCC have been described [9,10]. Addition of new biomarkers in the current staging systems is likely to improve the prognostic prediction of HCC patients and identify specific subgroups of tumor. MicroRNAs (miRNAs) are highly conserved, small non-coding RNA molecules of approximately 2
Data Loading...
